Although chemotherapy, targeted therapy and endocrine therapy decrease rate of disease
recurrence in most breast cancer patients, many patients exhibit acquired resistance …

Highlights•The treatment landscape of MBC has progressively widened in the last
years.•Several therapeutic strategies proved to be capable of prolonging survival of patients …

Background Approximately 40% of hormone receptor positive/human epidermal receptor 2
negative (HR+/HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol …

Endocrine therapy (ET) remains the mainstay of treatment for steroid hormone receptor-
positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) …

Checkpoint inhibitors have become an efficient way to treat cancers. Indeed, anti-CTLA-4,
anti-PD1, and anti-PDL-1 antibodies are now used as therapies for cancers. However, while …

Simple Summary Breast cancer remains the fourth-leading cause of death worldwide, and
therapeutic improvement is warranted. The phosphatidylinositol 3-kinase (PI3K) pathway is …

Around 75% of breast cancer (BC) patients have tumors expressing the predictive biomarker
estrogen receptor α (ER) and are offered endocrine therapy. One-third eventually develop …

Background: The prognostic relevance of the PIK3CA mutation together with PD-L1, c-Met,
and mismatch repair deficiency (dMMR) have not been fully investigated in Asian women …

Background Constitutive activation of PI3K signaling has been well recognized in a subset
of small cell lung cancer (SCLC), the cancer type which has the most aggressive clinical …

Phosphatidylinositol-3-kinase (PI3K) pathway hyperactivation has been associated with the
development of cancer and treatment resistance. PI3K inhibitors are now used to treat …